Glenmark Pharmaceuticals: The company’s arm, Glenmark Specialty, has entered into an exclusive licensing agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811), a HER2-targeting antibody drug conjugate. Newgen Software Technologies: The ... [10293 chars].. reed more